DOI: https://doi.org/10.36347/sjds.2026.v13i04.001

Pages: 68-86

This study evaluated the clinical efficacy and safety of hypersensitivity toothpaste containing 5% Calcium Sodium Phosphosilicate (CSPS) in reducing dentinal hypersensitivity (DH) and maintaining long-term relief across different treatment durations in Asian participants. An open-label, prospective, randomized, controlled study design was used over a 6-month period. Participants were randomized into two groups: Group A (1-month usage; 6-month follow-up; total 210 days) and Group B (3-month usage; 6-month follow-up; total 270 days). Participants brushed twice-daily using the modified Bass technique for their respective treatment periods. Afterward, they switched to a non-desensitizing toothpaste for a 6-month follow-up phase to evaluate the sustainability of pain relief. Assessments were performed at baseline, end-of-treatment (Day 30 for Group A; Day 90 for Group B), and at 3 and 6 months for both groups. Safety and compliance were monitored via clinical examinations and scheduled telephonic check-ins. Hypersensitivity toothpaste demonstrated significant improvements in all sensitivity parameters. At the end of treatment, Group B achieved an 86.39% reduction in air blast sensitivity, significantly outperforming Group A’s 58.61% reduction. Self-perceived sensitivity (VAS) showed a 91.26% reduction (11.38-fold) in Group B versus 79.58% in Group A. Post-discontinuation, Group B exhibited superior durability with no recurrence reported at the 3-month follow-up, whereas Group A experienced significant recurrence by the 3-month time-point. By the end of 6 months, only 21.82% of Group B participants required re-treatment compared to 68.33% of Group A. Secondary benefits included 100% resolution of bad breath and significant improvements in perceived gingival strength. No local intolerance or adverse events (AEs/SAEs) were reported, confirming a favourable safety profile. Hypersensitivity toothpaste offers superior management of dentinal hypersensitivity through its bioacti